Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $10.00 price target on the stock. D. Boral Capital’s price target indicates a potential upside of 224.68% from the stock’s previous close.

ANIX has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday. Maxim Group started coverage on shares of Anixa Biosciences in a research note on Friday, March 21st. They issued a “buy” rating and a $10.00 target price on the stock.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $3.08 on Wednesday. The stock has a market cap of $99.17 million, a price-to-earnings ratio of -7.90 and a beta of 0.86. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The business’s 50-day simple moving average is $2.96 and its 200 day simple moving average is $3.01.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, equities research analysts predict that Anixa Biosciences will post -0.41 EPS for the current year.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares in the company, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Amit Kumar purchased 43,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were bought at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 75,289 shares of company stock worth $177,021 over the last ninety days. 25.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANIX. Renaissance Technologies LLC lifted its stake in Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after buying an additional 3,900 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the 3rd quarter worth about $34,000. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter worth about $26,000. LPL Financial LLC lifted its position in Anixa Biosciences by 37.2% in the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after purchasing an additional 11,633 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its stake in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.